Search

CN-122012486-A - Biological envelope state probiotics microcapsule and application thereof in improving probiotic tolerance

CN122012486ACN 122012486 ACN122012486 ACN 122012486ACN-122012486-A

Abstract

The invention discloses a biological envelope state probiotics microcapsule and application thereof in improving probiotic tolerance, belonging to the technical field of microorganism preservation and maintenance. The biological film state probiotic microcapsule is prepared by mixing a probiotic suspension and a polysaccharide solution, then contacting the mixed solution with a cross-linking agent solution for cross-linking to obtain a polysaccharide cross-linked gel microcapsule, regulating the pH of a complex culture medium to 5-9, and then adding the polysaccharide cross-linked gel microcapsule for culturing to obtain the biological film state probiotic microcapsule. The microcapsule has excellent tolerance to gastric juice and bile salt, so that the problem of low survival rate of probiotics in gastrointestinal tract environment is solved.

Inventors

  • Yuan Yongkai
  • SONG YINGCHUN

Assignees

  • 青岛农业大学

Dates

Publication Date
20260512
Application Date
20260413

Claims (10)

  1. 1. The biological envelope state probiotics microcapsule is characterized by being prepared by the following method: Mixing the probiotic bacterial suspension with a polysaccharide solution, then contacting the mixed solution with a cross-linking agent solution for cross-linking to obtain a polysaccharide cross-linked gel microcapsule, regulating the pH of a complex culture medium to 5-9, and then adding the polysaccharide cross-linked gel microcapsule for culturing to obtain the biofilm-state probiotic microcapsule.
  2. 2. The biofilm state probiotic microcapsule according to claim 1, characterized in that the probiotic comprises at least one of lactobacillus, bifidobacterium.
  3. 3. The biofilm state probiotic microcapsule according to claim 1, wherein the polysaccharide is at least one of sodium alginate, pectin, carrageenan.
  4. 4. The biofilm-state probiotic microcapsule according to claim 1, wherein the bacterial content in the probiotic bacterial suspension is at least 1×10 8 CFU/mL, the mass volume concentration of the polysaccharide solution is 0.3-5%, and the volume ratio of the probiotic bacterial suspension to the polysaccharide solution is 1 (10-30).
  5. 5. The biofilm-state probiotic microcapsule according to claim 1, wherein the cross-linking agent solution is at least one of a calcium chloride aqueous solution, a calcium lactate aqueous solution and a strontium chloride aqueous solution, and the mass volume concentration of the cross-linking agent solution is 0.5-8%.
  6. 6. The biofilm state probiotic microcapsule according to claim 1, wherein the biofilm state probiotic microcapsule is crosslinked by dripping, spraying dripping or peristaltic pump dripping, and the crosslinking time is 10-60 min.
  7. 7. The biofilm state probiotic microcapsule according to claim 1, wherein the mass-volume ratio of the polysaccharide cross-linked gel microcapsule to the complex culture medium is 1 (5-20), g/mL.
  8. 8. The biofilm state probiotic microcapsule according to claim 1, wherein the complex culture medium is MRS broth or other culture medium capable of supporting the growth of probiotics, and the culture condition is anaerobic culture for 12-72 hours at 30-45 ℃.
  9. 9. Use of a biofilm state probiotic microcapsule according to any one of claims 1-8 for improving probiotic tolerance.
  10. 10. Use of a biofilm state probiotic microcapsule according to claim 9 for increasing probiotic tolerance, wherein said tolerance is processing tolerance or gastrointestinal digestive tolerance.

Description

Biological envelope state probiotics microcapsule and application thereof in improving probiotic tolerance Technical Field The invention belongs to the technical field of microorganism preservation and maintenance, and particularly relates to a biological envelope state probiotic microcapsule and application thereof in improving probiotic tolerance. Background Probiotics (e.g. lactobacillus, bifidobacterium) have a number of potential health effects of regulating intestinal flora, improving barrier function etc., but they function on the premise that they reach the intestinal tract in a sufficient number of viable bacteria. Oral probiotics are susceptible to inactivation by gastric acid and bile salt damage as they pass through the gastrointestinal tract. In order to improve the survival rate, gel embedding techniques such as calcium alginate are widely used. However, ordinary gel entrapment may still undergo swelling and degradation under extreme pH or bile salt stress, and the prior art lacks precise regulation of microenvironment inside the gel and biofilm formation, resulting in limited protective effects. Therefore, aiming at the problems of low survival rate of free probiotics and common embedded probiotics in processing (such as freeze-drying), storage and gastrointestinal tract environments, insufficient mechanical strength of gel, difficult controllable induction of a biological film and the like in the prior art, the invention provides a probiotic microcapsule which induces the formation of the biological film and constructs a 'biological film-gel' composite barrier through pH regulation and double culture so as to improve the tolerance of the probiotics, and has important significance and value. Disclosure of Invention The invention provides a biological envelope state probiotics microcapsule, which is prepared by the following method: Mixing the probiotic bacterial suspension with a polysaccharide solution, then contacting the mixed solution with a cross-linking agent solution for cross-linking to obtain a polysaccharide cross-linked gel microcapsule, regulating the pH of a complex culture medium to 5-9, and then adding the polysaccharide cross-linked gel microcapsule for culturing to obtain the biofilm-state probiotic microcapsule. In the technical scheme, the probiotics comprise lactobacillus and/or bifidobacterium, preferably at least one of lactobacillus rhamnosus GG (LGG), lactobacillus rhamnosus LRa05, lactobacillus rhamnosus WKA55, lactobacillus plantarum Lp90, lactobacillus plantarum CW006, lactobacillus plantarum Lp05, lactobacillus gasseri LG08, lactobacillus acidophilus LA85, lactobacillus acidophilus LA05 and bifidobacterium breve BBr 60. In the above technical scheme, the polysaccharide is at least one of sodium alginate, pectin and carrageenan. In the technical scheme, the bacterial content in the probiotic bacterial suspension is at least 1 multiplied by 10 8 CFU/mL, the mass volume concentration of the polysaccharide solution is 0.3-5%, and the volume ratio of the probiotic bacterial suspension to the polysaccharide solution is 1 (10-30). In the technical scheme, the cross-linking agent solution is an aqueous solution containing divalent metal ions, preferably at least one of a calcium chloride aqueous solution, a calcium lactate aqueous solution and a strontium chloride aqueous solution, and the mass volume concentration of the cross-linking agent solution is 0.5-8%. In the technical scheme, the volume ratio of the mixed solution to the cross-linking agent solution is 1 (5-20), and is preferably 1:10. In the technical scheme, the crosslinking is carried out by adopting a dripping mode, a spraying dripping mode or a peristaltic pump dripping mode, and the crosslinking time is 10-60 min. In the technical scheme, the mass volume ratio of the polysaccharide crosslinked gel microcapsule to the complex culture medium is 1 (5-20), g/mL, preferably 1:10, g/mL. In the technical scheme, the complex culture medium is MRS broth or other culture medium capable of supporting the growth of probiotics, and the culture condition is anaerobic culture for 12-72 hours at 30-45 ℃. In the technical scheme, the pH value of the complex culture medium is regulated by adopting acid and alkali, wherein the acid comprises inorganic acid and/or organic acid, the inorganic acid comprises hydrochloric acid, phosphoric acid or sulfuric acid, the organic acid comprises lactic acid, citric acid, acetic acid or malic acid, the alkali comprises inorganic alkali and/or organic alkali, the inorganic alkali comprises sodium hydroxide, potassium hydroxide, sodium carbonate or sodium bicarbonate, and the organic alkali comprises triethanolamine or ammonia water. The invention provides application of the biofilm-state probiotic microcapsule in improving probiotic tolerance, wherein the tolerance is processing tolerance or gastrointestinal tract digestive tolerance, the processing tolerance refers to tolerance to enviro